CSL partners with Alentis Therapeutics to co-develop lixudebart, while Jiangsu Nhwa licenses a clinical-stage sleep disorder candidate to Somnivera.
Feature|Articles|February 18, 2026
- Pharmaceutical Executive: April 2026
- Volume 46
- Issue 3
From Sun Belt Boom to Biotech Hub: Why Southern Florida’s Moment has Arrived
Author(s)Daniel Teper, PharmD, MBA, Raquel Cabo
Greater Miami is rapidly emerging as an international biotech hot spot—as capital, talent, and infrastructure converge to transform the region from a tourism-driven economy into a globally connected life sciences innovation hub.
Advertisement
Advertisement
Southern Florida is experiencing one of the most significant economic transformations in the US. Once viewed primarily through the lens of tourism, wealth management, and sunshine-migration, the region is increasingly attracting some of the world’s most influential companies; it is a shift that reflects deep structural changes in how and where innovation chooses to cluster.
Related to this article
Foghorn Therapeutics and Eli Lilly are discontinuing their SMARCA2 degrader Fhd-909 after Phase I data fell short on efficacy.
Novo licensed Hengrui's once-weekly oral GLP-1/GIP dual agonist HRS-1596 in a deal worth up to $2.6 billion, while AstraZeneca invested $2 billion in Summit Therapeutics to pair ivonescimab with its antibody-drug conjugate portfolio.
Merck has acquired exclusive global rights to SciBrunch's preclinical KRAS G12D inhibitor SPR2015.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
Why effective RWD linkage starts with a specific research objective — and how tokenization, clean rooms, and AI make it possible.
CORXEL’s Dr. Bo Liang on why GLP-1 therapies are a broader chronic disease platform — not just obesity drugs — with benefits across cardiovascular, renal, and metabolic disease.
Why GLP-1s achieving bariatric surgery-level efficacy is the field's most surprising advancement of the past decade.
Advertisement
Advertisement